Mayadev JS, Enserro D, Lin YG, et al. - In this prospective phase 1 trial carried out in 29 Gynecology Oncology Cooperative Group member institutions from December 18, 2012, to August 31, 2016, on 34 women with International Federation of Gynecology and Obstetrics stage IB2 to IVA cervical cancer with positive pelvic lymph nodes (LNs), para-aortic LNs, or both, experts evaluated the safety of sequential immunotherapy following chemoradiotherapy (CRT) and examined HPV genotype and HLA allele status on survival and programmed cell death 1 (PD-1) expression prior to and following CRT and sequential immunotherapy. Findings imply that for curative-intent treatment of people with cervical cancer, the use of immunotherapy following CRT is sustainable and efficient. Moreover, results revealed that PD-1 was upregulated after CRT and nurtured with following ipilimumab therapy. Thus, in people with node-positive cervical cancer, these immune findings could aid in supervising prospective therapies to provide the activated T-cell phenotype.